Overview

Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's ondansetron 24 mg tablets to GSK's Zofran® 24 mg tablets following a single, oral 24 mg (1 x 24 mg) dose administered under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Ondansetron